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Abstract. Background: Searching for additional therapeutic
tools to fight breast cancer, we investigated the effects of
vitamin D-binding protein-derived macrophage activating
factor (DBP-MAF, also known as GcMAF) on a human breast
cancer cell line (MCF-7). Materials and Methods: The effects
of DBP-MAF on proliferation, morphology, vimentin
expression and angiogenesis were studied by cell proliferation
assay, phase-contrst microscopy, immunohistochemestry and
western blotting, and chorioallantoic membrane (CAM)
assay. Results: DBP-MAF inhibited human breast cancer cell
proliferation and cancer cell-stimulated angiogenesis. MCF-
7 cells treated with DBP-MAF predominantly grew in
monolayer and appeared to be well adherent to each other
and to the well surface. Exposure to DBP-MAF significantly
reduced vimentin expression, indicating a reversal of the
epithelial/mesenchymal transition, a hallmark of human
breast cancer progression. Conclusion: These results are
consistent with the hypothesis that the known anticancer
efficacy of DBP-MAF can be ascribed to different biological
properties of the molecule that include inhibition of tumour-
induced angiogenesis and direct inhibition of cancer cell
proliferation, migration and metastatic potential. 
Breast cancer is the most common type of cancer in women
and one of the most common causes of cancer death. This
leads to the continuous search for additional therapies that
could be used as a complement to or alternative to surgery,
radiation therapy and conventional chemotherapy. Among
these novel approaches, those that target the immune system,
often referred to as immunotherapy, and tumour-induced
angiogenesis, appear promising.
Vitamin D-binding protein-derived macrophage-activating
factor (DBP-MAF, also known as GcMAF) seems to be a good
candidate for both immunotherapy and antiangiogenic therapy
in that it has the ability to stimulate macrophages (1), and
inhibit angiogenesis (2-5). The effects of DBP-MAF on 16
non-anaemic women who received weekly administration of
DBP-MAF as treatment for metastatic breast cancer were
recently described. Such a treatment yielded significant results,
mainly attributed to activation of tumouricidal macrophages
(6). It noteworthy, however, that the anti-angiogenic properties
of DBP-MAF might also have contributed to these results, in
particular considering that angiogenesis plays a key role in
breast cancer progression (7). In fact, another recent study
investigating the effects of DBP-MAF on tumour growth in a
severe combined immunodeficiency (SCID) mouse xenograft
model of human hepatocellular carcinoma (HCC) reported that
the tumours in the treatment group had fewer microvessels than
those in the untreated control group (8). In addition to these
indirect anticancer properties, it was recently demonstrated that
DBP-MAF directly inhibited proliferation, migration and
metastatic potential of transformed cells, with particular
reference to prostate cancer cells (9). 
Therefore, based on these promising results, we decided
to investigate the effects of a commercially available DBP-
MAF preparation on a widely studied human breast cancer
cell line MCF-7, focusing on the effects on proliferation,
morphology, vimentin expression and cancer cell-induced
angiogenesis. The MCF-7 cell line was chosen as an
experimental model because of its characteristics that help
to distinguish the effects of DBP-MAF from those of vitamin
D (see the Discussion section).
Materials and Methods
Commercially available DBP-MAF and vitamin D-binding protein
(VDBP), i.e. the precursor of DBP-MAF, were obtained from
Immuno Biotechnology (Dover, Kent, UK). All other common
reagents were from Sigma Aldrich (Milan, Italy).
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Cell line. MCF-7 cells were obtained from the Istituto
Zooprofilattico Sperimentale della Lombardia e dell’Emilia-
Romagna, Brescia, Italy. Cells were routinely maintained at 37˚C in
a humidified atmosphere of 5% CO2 in Eagle’s minimun essential
medium in Earle’s Balanced salt solution, supplemented with 1 mM
sodium pyruvate, 10% foetal bovine serum (FBS), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA,
USA). Experiments with DBP-MAF were performed medium
containing in 1% FBS after 24 h starvation in serum-free medium.
In all experiments, control cells were treated with VDBP at the same
concentration as that of DBP-MAF (0.4 ng/ml-40 ng/ml). We chose
this procedure in order to rule out the possibility that the observed
effects were due to non-specific protein interactions.
Cell proliferation. Assessment of cell proliferation was determined
by Calbiochem Rapid Cell Proliferation Kit (Calbiochem, D.B.A.,
Milan, Italy) (10) and by direct cell counting.  For this latter
procedure, MCF-7 cells (2×105 per well) were seeded in 24-well
plates and the cell number assessed after 72 h using a
haematocytometer. For both assessments, each condition was
replicated in quadruplicate samples and each experiment was
replicated three times. Differences between experimental values
were evaluated by the Student’s t-test.
Cell morphology. Cell morphology was studied by phase-contrast
microscopy using an Optika inverted microscope (Model XDS-2;
Optika Microscopes, Bergamo, Italy). This microscope had a
positive-phase plate for phase-contrast imaging below a long working
distance condenser lens, and an 8 Mp digital camera with LCD
Screen (Optika Microscopes). The light source was a 6V/30W
halogen pre-centered illuminator, with adjustable intensity. Phase-
contrast imaging was performed on living cells without any fixation
or treatment. A series of digital images of living cells were recorded
for each experimental point and the most representative were chosen. 
Papanicolaou staining was also performed. This staining results in
very transparent cells, such that even thicker specimens with
overlapping cells could be recorded. Briefly, cells were stained with
Harris haematoxylin as nuclear stain. Orange G and EA-65 (Light
Green, Bismarck Brown, and Eosin) were used for cytoplasmic
staining (Sigma Aldrich, Milan, Italy). Slides were mounted with
permanent mounting medium and observed under light microscopy
(Nikon Instruments SpA, Milan, Italy).
Vimentin expression. Vimentin expression was studied by
immunohistochemistry and by western blotting. For immunohisto-
chemistry, a monoclonal primary antibody against human vimentin
(Thermo Scientific, Fremont, CA, USA) diluted 1:100 was used;
incubation was performed for 20 min at room temperature and it was
followed by incubation with a goat anti-polyvalent horseradish
peroxidase-conjugated antibody (Ultravision Plus Detection kit;
Thermo Scientific). Cells were then observed under a light microscope
(Nikon Instruments SpA).
Western blotting analysis was performed after homogenizing
cells in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.25% sodium dodecyl
sulfate) supplemented with a protease inhibitor cocktail (Sigma
Aldrich), and after centrifugation for 15 min at 4˚C at 10000×g. The
supernatant was collected and the protein concentration was
measured using Bradford reagent (Sigma Aldrich). Aliquots
containing 20 μg of protein were diluted in 4× reducing Laemmli’s
sample buffer (250 mM Tris-HCl, pH 6.8, 20% glycerol, 8%
Sodium Dodecyl Sulphate (SDS), 20% 2-mercaptoethanol, 0.008%
bromophenol blue) and loaded onto 12% SDS-PolyAcrylamide Gel
Electrophoresis (PAGE). Proteins were then transferred onto
polyvinylidene difluoride membranes (Hybond-P; Amersham
Pharmacia Biotech, Buckinghamshire, UK). Membranes were
blocked for 1 h at room temperature in 5% BSA-TPBS buffer (0.1%
Tween-20, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5), washed in
TPBS, and incubated at 4˚C overnight with anti-vimentin primary
antibody (Santa Cruz Biotechnology; Santa Cruz, CA, USA)
(dilution 1:1000). Each experiment was repeated three times. 
Densitometric analysis of vimentin was performed by Scion
Image software (Scion Corporation, Frederick, MD, USA) for
western blotting, β-actin signal was used as reference. 
Angiogenic activity. Angiogenesis was studied by chorioallantoic
membrane (CAM) assay (11). Briefly, fertilized chicken eggs were
incubated at 37˚C at constant humidity. On day 3, a square
window was opened in the shell, and 2 to 3 ml of albumen were
removed to allow detachment of the developing CAM from the
shell. The window was sealed with a glass coverslip of the same
dimension, and the eggs were returned to the incubator. On day 8,
eggs were treated with 1 mm3 sterilized gelatin sponges (Gelfoam;
UniPharma SA, Barbengo, Switzerland) placed on top of the
growing CAM and loaded with: 5 μl PBS as negative control; 5 μl
DBP-MAF (40 ng/ml); 5 μl MCF-7 suspension (6×104 cells per
sponge).
CAMs were examined daily until day 12 and photographed in
ovo with a stereomicroscope equipped with a camera and image
analyzer system (Nikon Instruments SpA). At day 12, the
angiogenic response was evaluated by counting the number of
vessels, centering the sponges within the focal plane of the CAM
(circumfocal microvessel number, CFMN) (12). Mean±standard
deviation (SD) were evaluated and the statistical significance of the
differences between the counts was determined by Student’s t-test.
Results
Effects of DBP-MAF on MCF-7 cell proliferation. MCF-7
human breast cancer cell proliferation was significantly
inhibited by 72 h incubation with DBP-MAF in a dose-
dependent manner. Figure 1A shows the results obtained by
measuring proliferation with the colorimetric assay described
in the Materials and Methods. DBP-MAF (at 0.4 ng/ml and
40 ng/ml) inhibited cell proliferation in a manner similar to
that obtained with vitamin D (1,25(OH)-2D-3 at 100 nM and
1 μM), a  known inhibitor of MCF-7 cell proliferation (13).
Vitamin D (1 μM) and DBP-MAF (40 ng/ml) administered
together led to almost total inhibition of cell proliferation in
comparison to control cells. However, the  results obtained
with vitamin D at a concentration of 100 nM should be
considered with care, since this concentration is well above
the physiological level. Qualitatively similar results were
obtained by counting the cell numbers after 72 h DBP-MAF
treatment (Figure 1B). With this assay, significant inhibition
of cell proliferation was also observed with 0.4 ng/ml DBP-
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MAF, a concentration  similar to that required to stimulate
human peripheral blood mononuclear cells (5). Taken
together, these results demonstrate that DBP-MAF directly
inhibited MCF-7 cell proliferation in a manner analogous to
that observed by Gregory et al. for LnCaP prostate cancer
cells (9).
Effects of DBP-MAF on MCF-7 cell morphology. Cell
morphology was first studied in living MCF-7 cells observed
under phase-contrast light microscopy. In other words, in
these experiments cells had not undergone any preparation for
microscopy, i.e. washing, fixation or staining. Figure 2A
shows control cells after 72 h incubation. As expected, cells
did not show contact inhibition and formed clusters (indicated
by arrows in the figure). Cell morphology and size were
nonhomogeneous. Figure 2B shows MCF-7 cells treated with
40 ng/ml DBP-MAF for 72 h. No major clusters were
observed and the culture appeared as a monolayer of cells,
regularly polygonal and uniform in morphology and size. The
DBP-MAF concentration required to induce the
morphological changes depicted in Figure 2B was higher than
that required to inhibit cell proliferation and identical to that
required to inhibit angiogenesis [see following paragraph and
(5)]. It is worth noting, however, that minor, although evident,
morphological changes were also observed at a lower
concentration (0.4 ng/ml DBP-MAF). Figure 2C shows
phase-contrast microscopy of control MCF-7 cells, whereas
Figure 2D shows cells treated with 0.4 ng/ml DBP-MAF for
72 h. MCF-7 cells treated with DBP-MAF also appeared less
nonhomogeneous in morphology and size compared with
control cells. Morphological changes were also apparent after
24 h treatment by phase-contrast microscopy (Figure 3). In
this case, a higher concentration of DBP-MAF was required
to induce observable significant changes. Figure 3A shows
control MCF-7 cells, whereas Figure 3B shows cells treated
with 40 ng/ml DBP-MAF for 24 h. The differences in
homogeneity, morphology and size are evident. 
We then examined MCF-7 cells using classical
Papanicolaou stain (Figure 4). In this case, cell cultures
underwent washing, fixation and staining. Figure 4A shows
control MCF-7 cells at 72 h incubation. Cells grew one on
top of the other, forming typical clusters as indicated by
arrows. Cell size, morphology and staining were
nonhomogeneous. Large empty spaces between clusters
suggest poor adherence to the well surface. This particular
feature was not apparent under  phase-contrast microscopy
since it was evident only after washing the cultures during the
staining procedure. Figure 4B shows cells treated with 40
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Figure 1. Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell proliferation.
A: Assessment of cell proliferation by methyl-thiazol-tetrazolium (MTT)-based assay. Treatment columns 1: control (VDBP, 40 ng/ml); 2: DBP-MAF,
0.4 ng/ml.; 3: vitamin D (1,25(OH)-2D-3), 100 nM; 4: DBP-MAF, 40 ng/ml; 5: 1,25(OH)-2D-3, 1 μM; 6: 1,25(OH)-2D-3, 1 μM + DBP-MAF, 40
ng/ml. Values represent means±SEM (n=12). *p<0.05 vs. Control; **p<0.01 vs. control. B: Assessment of cell proliferation by cell counting. MCF-
7 cells (2×105 cells per well) were seeded in 24-well plates and cell number after 72 h assessed using a haematocytometer. Treatment columns 1:
control; 2: DBP-MAF 0.4 ng/ml. Values represent means±SEM (n=12). **p<0.01 vs. control.
ng/ml DBP-MAF for 72 h. Cells were smaller, regularly
polygonal and uniform in size and morphology, and the
culture grew as a monolayer. Cells appeared to be well
adherent to each other and to the well surface, as suggested
by the absence of large empty spaces. 
Effects of DBP-MAF on vimentin expression in MCF-7 cells.
Although the MCF-7 line is of epithelial origin and retains
several characteristics of differentiated mammary epithelium,
it expresses vimentin, the archetypal mesenchymal marker
that is also over expressed in breast carcinomas undergoing
epithelial/mesenchymal transition and exhibiting increased
cell migration and invasion. In fact, vimentin expression is
considered a hallmark of human breast cancer progression
and, during progression toward a more malignant phenotype,
the cell intermediate filament status changes from a keratin-
rich to a vimentin-rich network (14).
Our hypothesis that DBP-MAF-induced morphological
changes could be interpreted as if DBP-MAF reverted cancer
cell malignant phenotype was corroborated by the study of
vimentin expression. Figure 5 demonstrates that exposure to 40
ng/ml DBP-MAF for 72 h significantly reduced vimentin
expression in MCF-7 cells. Figure 5A (immunohistochemistry)
shows control MCF-7 cells; significant brown staining was
observed, indicating strong vimentin expression. In this case,
large empty spaces after repeated washing also suggest poor
adherence to the well surface. Figure 5B (immunohisto-
chemistry) shows MCF-7 cells treated with 40 ng/ml DBP-
MAF for 72 h. Brown staining was less pronounced and cells
also appeared more uniform in morphology and size, and more
adherent to the substrate. Densitometric analysis (Figure 5C)
confirmed these observations. Western blot analysis (Figure
5D), yielded results consistent with those obtained by
immunohistochemistry.
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Figure 2. Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology
under phase-contrast light microscopy. MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A; arrows indicate
cell clusters), 40 ng/ml DBP-MAF (B), 0.4 ng/ml VDBP (C), and with 0.4 ng/ml DBP-MAF (D). Scale bar=50 μm.
Effects of DBP-MAF on breast cancer cell-stimulated
angiogenesis. It is well reported that DBP-MAF inhibits
angiogenesis, and inhibition of angiogenesis is considered a
key feature of its anticancer properties (2, 3, 8, 15). It is worth
noting, however, that until recently, DBP-MAF was not
commercially available and each laboratory had to extract and
purify DBP-MAF using complex procedures that varied from
laboratory to laboratory (8, 9). An example of the difficulties
in preparing DBP-MAF is reported in (16). Therefore, the
effects of commercially available DBP-MAF on cancer cell-
stimulated CAM assay, a reliable and inexpensive method to
study angiogenesis, have not yet been tested. In order to fill
this gap, we tested its effects both under basal conditions and
when administered together with MCF-7 cells. DBP-MAF did
not alter basal angiogenesis (Table I) or chick embryo
development (not shown). As expected, MCF-7 cells, directly
implanted in the CAM, strongly stimulated angiogenesis (Table
I), as previously described (11). In fact, it is well known that
MCF-7 cells produce pro-angiogenic factors (17), and
stimulation of angiogenesis by MCF-7 cells was comparable
to that induced by prostaglandin E1, a known inducer of
proangiogenic factor production (5). DBP-MAF (40 ng/ml)
significantly inhibited MCF-7-stimulated angiogenesis (Table
I). It is worth noting that the DBP-MAF concentration required
to achieve full inhibition of stimulated angiogenesis was 40
ng/ml, i.e. a concentration 100-fold higher than that required
to inhibit MCF-7 cell proliferation under our experimental
conditions. This DBP-MAF concentration, however, was
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Figure 4. Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology
after Papanicolaou stain under light microscopy. MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A; arrows
indicate cell clusters), and with 40 ng/ml DBP-MAF (B). Scale bar=25 μm.
Figure 3. Effects of 24 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology
under phase-contrast light microscopy. MCF-7 cells treated for 24 h with 40 ng/ml VDBP Vitamin D-binding Protein (VDBP) (control) (A) and with
40 ng/ml DBP-MAF (B). Scale bar=25 μm.
ANTICANCER RESEARCH 32: 45-52 (2012)
50
Figure 5. Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on vimentin expression in
MCF-7 cells. Immunohistochemistry of MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A) and with 
40 ng/ml DBP-MAF (B). Scale bar=25 μm. Densitometric analysis of vimentin expression determined by immunohistochemistry (C). Brown stained
areas of panels A (column 1, control), and B (column 2, DBP-MAF) were measured by Scion Image software and expressed as square pixels. Western
blot analysis and densitometric evaluation of vimentin expression (D). Band 1 and column 1 (densitometric analysis of the actual band) refer to MCF-
7 cells treated for 72 h with 40 ng/ml VDBP. Band 2 and column 2 refer to MCF-7 cells treated for 72 h with 40 ng/ml DBP-MAF. Areas of bands
1 (control), and 2 (DBP-MAF) were measured by Scion Image software and expressed as square pixels. Values in densitometric analyses indicate
means±SEM (n=3). *p<0.01 vs. control. Β-Actin signal was used for reference.
identical to that required to observe the major morphological
changes reported in Figures 2-4, as well as reduced vimentin
expression (Figure 5). This observation is consistent with
previous results demonstrating that the concentrations of DBP-
MAF required to inhibit angiogenesis in CAM assay or in other
assays were higher than those required to activate macrophages
or inhibit cancer cell proliferation (3, 4, 9). In addition, these
results, consistent with those reported in (2, 3, 8, 15), seem to
indicate that inhibition of angiogenesis by DBP-MAF is
independent of the pro-angiogenic factor(s) used to stimulate
angiogenesis in the different experimental models tested.
Discussion
The biological effects of DBP-MAF were first described in
1994 (18) and shortly afterward its anti/tumour properties in
BALB/c mice bearing Ehrlich ascites tumour were described
(19). Further studies on the effects of DBP-MAF on cancer
patients reported successful immunotherapy of prostate
cancer (20), and metastatic breast (6) and colon (21) cancer.
Accumulating evidence indicates that the anticancer efficacy
of DBP-MAF can be ascribed at least to three biological
properties of the molecule: i) activation of tumoricidal
macrophages; ii) inhibition of tumour-induced angiogenesis;
and iii) direct inhibition of cancer cell proliferation,
migration and metastatic potential. The direct inhibition of
cancer cell proliferation, however, before this study has been
described only for prostate cancer cells (9). 
Not surprisingly, the anticancer effects of DBP-MAF
attracted great attention and a quick search of the Internet
reveals that several cancer clinics in different countries are
currently proposing DBP-MAF as treatment for cancer
patients (http://www.klinik-st-georg.de/dr-douwes-informiert/
wahre-hilfe-bei-krebs/, http://immunemedicine.com/available-
therapies/gcmaf/, http://www.gcmaf.eu/info/index.php?option=
com_content&view=article&id=122&Itemid=56 web page
accessed on June 30th 2011). The interest for the therapeutic
potential of DBP-MAF is further demonstrated by the
applications for patents related to DBP-MAF use (for the latest
patent application see number 20110123591, publication date:
05/26/2011, by Knezevich and Silvetz, available at:
http://www.faqs.org/ patents/app/20110123591, web page
accessed on June 30th 2011). 
However, one major hindrance to basic and clinical
research on DBP-MAF, is that, so far, most laboratories have
produced their own DBP-MAF with different procedures, all
based on sequential deglycosylation of its precursor, i.e.
VDBP. As recently demonstrated by Ravnsborg et al. (16),
the sequence of deglycosylation is critical and this might
explain why different laboratories reported different specific
activities for DBP-MAF as far as biological effects were
concerned (3-5, 9). With the aim of allowing reproducibility
of our results, in this study, we used a commercially
available source of DBP-MAF to assess its effects on
cultured human breast cancer cells. Our results are in
agreement with the observation of Gregory et al. (9) who
demonstrated a direct inhibitory effect on prostate cancer
cells, and lend credit to the hypothesis that DBP-MAF has a
non type-specific anticancer activity. This hypothesis is
further reinforced by preliminary data indicating a direct
inhibitory effect of DBP-MAF on a human acute monocytic
leukemia cell line (Pacini et al., manuscript in preparation).
Our results also demonstrate for the first time that DBP-
MAF induced changes of several morphological features of
breast cancer cells, a phenomenon that we interpreted as
reversal of the malignant phenotype. This phenomenon was
consistent with the observation that DBP-MAF reduced the
expression of vimentin, a hallmark of malignant progression
(14), since trans-differentiation from an epithelial to a
mesenchymal phenotype is responsible for increased
aggressiveness and metastatic propensity (22). 
We hypothesize that the observed effects of DBP-MAF on
MCF-7 cells may be ascribed to stimulation of a cell surface
receptor, with triggering of a cascade of intracellular
signalling, possibly involving cAMP production, as we
observed in human mononuclear cells (5). In fact, MCF-7
cells, unlike other human breast cancer cell lines, do not
internalize DBP (23) and therefore it is not likely that they
internalize DBP-MAF. It is worth noting that among
different human breast cancer cell lines, MCF-7 cells were
chosen as an experimental model in this study because of
this feature, which helps distinguish the effects of DBP-MAF
from those of vitamin D possibly bound to DBP-MAF. In
fact, MCF-7 cells are cultured in medium containing FBS,
and FBS contains vitamin D (24) as well as DBP (23).
In conclusion, our results support and reinforce the
hypothesis that DBP-MAF is a molecule endowed with
multiple biological activities relating to its anticancer
properties. It can be hypothesized that future directions of
research in this field will involve the study of the effects of
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Table I. Quantitative evaluation of angiogenesis on chorioallantoic
membrane (CAM) assay. Effects of Vitamin D-binding protein-derived
macrophage-activating factor (DBP-MAF) on MCF-7-stimulated
angiogenesis.
Treatment Circumfocal microvessel number
PBS 15.3±1.4
DBP-MAF (40 ng/ml) 16.4±1.8
MCF-7 28.5±1.3
MCF-7 + DBP-MAF (40 ng/ml) 16.7±1.0*
Data are the average number of blood vessels derived from scoring
small (≤1 mm diam.), large (>1 mm diam.), and tortuous microvessels
surrounding the sponge. Data are reported as means±SEM (n=18).
*p<0.02 vs. MCF-7 cells alone.
DBP-MAF in wound-healing, migration and cell death
assays, and in xenograft animal models  in order to further
characterize the multifaceted properties of DBP-MAF.
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